Latest Breaking News On - Best available therapy - Page 1 : comparemela.com

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or…

SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized, controlled, registrational Phase II study of the company's novel drug candidate, olverembatinib (R&D code: HQP1351), in.

Qian jiangUnited statesSan diegoHong kongInnovent biologicsXiaojun huangAscentage pharmaYifan zhaiPrnewswire ascentage pharmaEastern cooperative oncology groupDana farber cancer instituteMd anderson cancer centerNational reimbursement drug listMajor nationalChina national medical products agencyUniversity people hospital

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesHong kongQian jiangJianyong liJianxiang wangPrnewswire ascentage pharmaHuafeng wangElias jabbourXiaojun huangJie jinKeshu zhouSikander ailawadhiXiaoyuan gongYifan zhaiLiposome mitoxantrone

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesUnited kingdomQian jiangHong kongHagop kantarjianJianyong liPrnewswire ascentage pharmaYifan zhaiJianxiang wangAscentage pharmaLiposome mitoxantroneInnovent biologicsSikander ailawadhiHuafeng wangHongsheng zhou

Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

Helen ajufoSpleen volume reductionPredicts overall survivalBest available therapy

Clinical evaluation of meropenem-vaborbactam for UTI

Clinical efficacy has been demonstrated and suggests the use of meropenem-vaborbactam for the treatment of cUTI is an option.

New yorkUnited statesNew delhiMeropenem vaborbactamMonte carloAsia pacificCenters for diseaseAmerican society for microbiologyEuropean congressWorld health organizationDrug administrationLaboratory standards instituteChronic health evaluationDisease controlWorld healthClinical microbiology